The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi-omic analysis and overall survival update of phase II TRIDENT study: Durvalumab plus olaparib in extensive-stage small-cell lung cancer (ES-SCLC).
 
Yuanyuan Zhao
No Relationships to Disclose
 
Yan Huang
No Relationships to Disclose
 
Hong Liu
No Relationships to Disclose
 
Bijing Xiao
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Akeso Biopharma; AstraZeneca; CHINA SHIYAO PHARMA; HenRui; Roche; Sichuan Biokin Pharmaceutical
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); QiLu Pharmaceutical (Inst); Sichuan Biokin Pharmaceutical, (Inst); Sichuan Kelun-Biotech Biopharmaceutical (Inst)